Peptide · Fact sheet

Cagrilintide

Also known as AM833 · long-acting amylin analog

Cagrilintide is an investigational amylin analog—not an FDA-approved weight-loss medicine. Phase 3 trials report substantial average weight reduction alone and with semaglutide, while tolerability, long-term outcomes, and regulatory review remain separate questions.

In clinical trialsModerate human evidence

What is Cagrilintide?

Cagrilintide is engineered to activate amylin receptors for longer than natural amylin.

It is being developed both as a single investigational drug and together with semaglutide under the name CagriSema; combination results cannot be attributed entirely to cagrilintide.

Benefits & claims

The amylin pathway offers a distinct satiety signal that can complement GLP-1 biology.

Large Phase 3 programs have moved the candidate well beyond early mechanism studies, but online access or combination claims are not evidence of approval.

What the evidence supports

  • REDEFINE 1 reported meaningful average weight reduction with cagrilintide alone and a larger effect with the CagriSema combination.
  • The combination also improved glycemic outcomes in a Phase 3 diabetes trial, but that does not isolate the contribution of each component.
Research areas
  • Obesity and overweight
  • Type 2 diabetes
  • Blood pressure and cardiometabolic markers
  • Combination treatment with semaglutide
  • Chronic weight management
  • Type 2 diabetes
  • Fixed-combination metabolic treatment

Dosage & frequency

Human study context

Cagrilintide remains a trial medicine. Its study regimens and the cagrilintide–semaglutide combination do not create an approved standalone prescription.

REDEFINE 1 / CagriSema study

Adults without diabetes meeting study obesity or overweight criteria

Amount
Target cagrilintide 2.4 mg, alone or with semaglutide 2.4 mg in distinct study groups
Frequency
Once weekly in a 68-week main trial
Route studied or labeled
Subcutaneous

Trial had escalation and lifestyle interventions; combination findings do not establish a standalone prescription.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • CagriSema combines cagrilintide with semaglutide; combination results cannot isolate cagrilintide benefit.

Interactions & precautions

  • Combination-trial safety does not establish compatibility with arbitrary other amylin or GLP-1 medicines.

What is still unresolved

  • Final approved product, indication, dose schedule, and long-term combination safety remain unresolved.

Side effects & risks

  • Gastrointestinal adverse effects, including nausea and vomiting, were common in the development program.
  • Combination tolerability and treatment discontinuation affect how trial efficacy translates into practice.
  • Long-term and uncommon harms remain less characterized than for approved medicines.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Moderate human evidence

Large randomized Phase 3 studies show weight and glucose effects, including a cagrilintide-only group in REDEFINE 1. Regulatory review, long-term cardiovascular outcomes, and real-world safety are not yet established as they are for approved products.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Quieter food thoughts, with loose stools

After nine days with a product labeled cagrilintide, a person described much less food preoccupation and fewer cravings, with loose stools. They had previously tried several other weight-loss compounds.

Reported use in this account

Product
Product described as cagrilintide
Amount
1 mg was the stated starting amount
Frequency
Not specified clearly
Route
Injection; type not stated
Duration
Nine days at the time of the post

Other exposures described: Prior semaglutide, tirzepatide and retatrutide; the retatrutide reply does not establish concurrent frequency

This short, enthusiastic account is not a verified trial experience. Product identity, remaining effects of other compounds and longer-term outcomes are unclear.

Read the early appetite account
Mixed account · personal report

Very little appetite, but difficult daytime sleepiness

A commenter described two months of very low interest in food and difficulty staying awake during cagrilintide exposure.

Reported use in this account

Product
Product described as cagrilintide
Amount
1 mg, stated in a reply by the same commenter
Frequency
Not specified clearly
Route
Injection; type not stated
Duration
Not specified clearly

Diet, health history and product contents are unclear. The account cannot separate a direct effect from reduced food intake or other causes of fatigue.

Read the appetite-and-sleepiness comment
No noticeable effect · personal report

No noticeable effect despite repeated attempts

Another commenter reported trying cagrilintide repeatedly without noticing a result.

Reported use in this account

Product
Product described as cagrilintide
Amount
1 mg was one of the stated amounts tried
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Not specified clearly

The brief comment omits duration, formulation and other exposures. It cannot establish lack of efficacy in a clinical setting.

Read the no-result comment

Approval status

Cagrilintide and CagriSema remain investigational in the United States. Completed and ongoing Phase 3 trials do not equal FDA approval.

Late-stage clinical development

Cagrilintide and CagriSema have Phase 3 records and reports, but no FDA-approved product. Combination evidence should not be treated as cagrilintide-only approval.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether FDA will approve cagrilintide alone, CagriSema, both, or neither
  • Long-term cardiovascular and other clinical outcomes
  • How much benefit and risk come from each component of CagriSema
  • Durability after treatment ends

Summary

Cagrilintide remains investigational. Results for the CagriSema combination cannot be attributed to cagrilintide alone.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. clinical trialsClinicalTrials.gov: REDEFINE 1

    Phase 3 trial record covering cagrilintide, semaglutide, their combination, and placebo.

  2. pubmedREDEFINE 1 randomized Phase 3 report

    Large obesity trial reporting outcomes for the combination and individual components.

  3. pubmedREDEFINE 2 randomized Phase 3 report

    Controlled combination trial in adults with overweight or obesity and type 2 diabetes.

How we assess sources · Suggest a correction